Management of Hypertensive Cardiomyopathy

Understanding Hypertensive Cardiomyopathy

The European Society of Cardiology recommends that hypertensive cardiomyopathy be managed with aggressive blood pressure control, targeting BP <130/80 mmHg, along with lifestyle modifications to improve outcomes and prevent progression to heart failure 1, 2, 3
Progression to heart failure with preserved ejection fraction (HFpEF) in early stages is a characteristic of hypertensive cardiomyopathy 2
Potential advancement to dilated cardiomyopathy with systolic dysfunction in end-stage disease is a possible outcome of hypertensive cardiomyopathy 3

The European Heart Journal suggests that most patients with hypertensive LVH have maximal interventricular septal thickness <15mm, which distinguishes them from patients with hypertrophic cardiomyopathy 4, 5
Normal ECG or isolated voltage criteria without significant repolarization abnormalities can be used to diagnose hypertensive cardiomyopathy 4
Regression of LVH with tight BP control over 6-12 months supports hypertensive etiology 4, 5
Absence of family history of HCM suggests hypertensive cause 4

The American Heart Association recommends ACE inhibitors or ARBs as the cornerstone of therapy for hypertensive cardiomyopathy, reducing remodeling after myocardial injury and improving outcomes 1, 3
Beta-blockers are an essential component of therapy, reducing cardiovascular events and mortality in patients with hypertension and heart disease 1, 2, 3
Target resting heart rate between 50-60 beats per minute with beta-blockers 6
Carvedilol, metoprolol succinate, and bisoprolol have demonstrated mortality benefits in heart failure 6

The American College of Cardiology recommends thiazide or thiazide-type diuretics as first choice for BP control and prevention of heart failure 2, 3
Loop diuretics should be reserved for more severe heart failure or renal impairment, and combined with ACE inhibitor/ARB and beta-blocker 3, 6

Aldosterone antagonists are beneficial in patients with heart failure symptoms 2, 7
Hydralazine/isosorbide dinitrate should be considered as an addition to standard therapy in African American patients with NYHA class III or IV heart failure 6

Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) should be avoided due to negative inotropic effects that may worsen heart failure symptoms 6, 8
Clonidine and moxonidine should be avoided due to potential increased mortality in heart failure 6, 8
Alpha-blockers (e.g., doxazosin) are associated with increased risk of developing heart failure; use only if other agents are inadequate 6, 8

The American Heart Association recommends a primary target of <130/80 mmHg 6, 8
A more aggressive target of <120/80 mmHg may be considered in selected patients 6, 8

Sodium restriction is important for management of both hypertension and LV dysfunction 2, 3, 6
Exercise training, supervised with careful monitoring of BP response and ECG, reduces recurrent cardiac events in patients with LV dysfunction 2, 6
Additional lifestyle modifications, including management of dyslipidemia, diabetes mellitus, and obesity, and smoking cessation, are recommended 2